Australia's Plan to Cut Vitamin B6 Upper Limits by 72%: What It Means for Indian Supplement Buyers in 2026

Australia's National Health and Medical Research Council (NHMRC) has recommended reducing the safe daily upper intake level for vitamin B6 from 50mg to just 14mg — a 72% cut — after a six-month expert review found that cumulative supplement exposure is causing peripheral neuropathy in a growing number of Australians. The proposal is currently in public consultation, and if adopted, it will reshape how supplement manufacturers worldwide formulate B-complex, magnesium, and multivitamin products that are widely sold in India.

Indian consumers who routinely buy B-complex tablets, stress-support supplements, or protein powders — many of which are formulated to Australian or European standards — face direct practical implications from this shift.

Global Vitamin B6 Upper Intake Limits at a Glance

Before diving into the science and the regulatory timeline, it helps to see how Australia's proposed limit compares with other major jurisdictions. The gap between countries is striking.

Jurisdiction	Current Upper Limit (mg/day)	Notes
Australia (current)	50 mg	In force since 2006; under review
Australia (proposed)	14 mg	NHMRC recommendation, in public consultation (2026)
USA (FDA/FNB)	100 mg	Food and Nutrition Board guideline; unchanged
European Food Safety Authority (EFSA)	12.5 mg	Updated downward from 25 mg in 2023
France	12.5 mg	Aligned with EFSA 2023 update
Switzerland	15 mg	National limit
Netherlands	20 mg	National limit
Italy	10 mg	National limit
Belgium / Poland	6 mg	Among the most conservative in Europe
India (ICMR)	No formal UL published	Recommended dietary allowance ~2 mg/day for adults

Sources: Vitafoods Insights, TGA official safety update, NHMRC consultation document

Australia's proposed 14mg limit would place it squarely in the European regulatory camp and far below the American standard. India has no published formal upper limit for vitamin B6, which means Indian consumers have been largely unprotected by any regulatory ceiling — and the products they buy often reflect the more permissive US or older Australian benchmarks.

What Exactly Is Vitamin B6 and Why Does It Matter?

Vitamin B6 is a water-soluble, heat-sensitive vitamin that acts as a coenzyme in more than 150 enzymatic reactions, including the metabolism of amino acids, carbohydrates, and lipids, as well as the synthesis of neurotransmitters and haemoglobin. It exists as a group of six related compounds — pyridoxal, pyridoxine, pyridoxamine, and their 5'-phosphate forms — with pyridoxal 5'-phosphate (PLP) being the principal active form in human tissues, primarily stored in muscle bound to phosphorylase.

The body cannot produce B6 on its own, so dietary intake is essential. Natural food sources include meat, poultry, fish, eggs, legumes (chickpeas, lentils), vegetables (potatoes, spinach, kale), fruits (bananas, avocados), and fortified cereals. Bioavailability from a mixed diet is generally around 75%, per the NHMRC's draft chapter.

The recommended dietary intake (RDI) for adults is approximately 1.3 to 1.7mg per day — a figure that is not changing under the new proposal. What is changing is the ceiling: the maximum intake considered safe across the population.

What Triggered Australia's 72% Cut Proposal?

The NHMRC's working group, co-chaired by Professor Tim Green of Flinders University, spent six months reviewing global evidence before recommending the 14mg upper limit. The trigger was a documented rise in adverse event reports, most notably peripheral neuropathy — damage to the peripheral nerves (those outside the brain and spinal cord) that causes tingling, burning, numbness, pain, and in severe cases, impaired gait and permanent nerve damage.

"There is clear evidence that some people in Australia and New Zealand are experiencing adverse effects from excessive vitamin B6 intake, most notably peripheral neuropathy," Professor Green told Vitafoods Insights. "While vitamin B6 is an essential nutrient, the emerging evidence indicates that adverse effects can occur at lower intake levels than previously thought, particularly when people consume multiple supplements or fortified products containing vitamin B6 over extended periods," he said, as reported by Vitafoods Insights.

The key driver is cumulative exposure. Consumers are unknowingly stacking B6 across multiple products: a magnesium tablet, a B-complex, a protein powder, and an energy drink can together deliver well over 50mg per day — sometimes without the word "vitamin B6" appearing prominently on any single label. The NHMRC draft document notes that supplements may contain more than ten times the RDI for vitamin B6, whereas no natural food source comes close to that level.

The ABC's 7.30 programme documented the case of Dominic Noonan-O'Keefe, who described experiencing "lightning bolts through my body 24 hours a day" after unknowingly consuming too much B6 through supplements. More than two years after stopping, he still lives with balance and vision problems. ABC News reported that the NHMRC's review followed years of mounting concern and a November 2025 intervention by the Therapeutic Goods Administration (TGA).

Neurologist Matt Silsby, quoted in the same ABC report, said B6 toxicity typically causes "primarily sensory symptoms — pins and needles, prickling, or painful symptoms" — and in serious cases can lead to permanent nerve damage. He was careful to note that symptoms "may have very many causes" and that attribution requires clinical assessment.

What Are the TGA's New Sales Rules, and When Do They Kick In?

The Therapeutic Goods Administration (TGA) is Australia's national regulator for therapeutic goods, including medicines and supplements. In November 2025, the TGA amended its Poisons Standard to introduce a tiered access system for vitamin B6 products, with implementation set for 1 June 2027.

Under the new TGA framework:

• Products containing 50mg or less per recommended daily dose remain available for general retail sale.
• Products containing more than 50mg but not more than 200mg per recommended daily dose will require pharmacist supervision (reclassified as Pharmacist Only Medicines).
• Products containing more than 200mg per recommended daily dose require a doctor's prescription.

This is a separate regulatory action from the NHMRC's upper limit review. As Professor Green explained to Vitafoods Insights, the TGA's scheduling decision addresses access and labelling, while the NHMRC's proposed 14mg upper limit is a scientific reference value — "the highest average daily intake likely to pose no risk of adverse health effects in almost all individuals."

The TGA has confirmed it is waiting for the NHMRC recommendation process to be completed before committing to further regulatory action. The 14mg upper limit, if finalised, could trigger a second wave of regulatory tightening beyond what the June 2027 changes already mandate.

The Conversation's analysis of the TGA decision, authored by pharmacology experts, noted that the new prescription threshold of 200mg is approximately 117 times the recommended dietary intake — and that the combination of multiple low-dose products is precisely what regulators have failed to adequately address so far, as The Conversation reported.

How Does Australia's Proposal Compare with Europe and the USA?

Food regulation expert Luca Bucchini, founder of Hylobates Consulting, told Vitafoods Insights that the NHMRC's proposal reflects a broader global trend. "If Australia chooses to move to 14mg, they are clearly positioning themselves closer to the conservative European regulatory mindset than the legacy US approach," he said.

The European Food Safety Authority (EFSA) updated its tolerable upper intake level for vitamin B6 in 2023, reducing it from 25mg to 12.5mg per day. There is no harmonised EU-wide limit for food supplements — the European Commission is still working on this — but most member states have adopted restrictive national limits, ranging from France's 12.5mg to Belgium's 6mg.

The United States Food and Nutrition Board, by contrast, maintains a 100mg per day upper limit — more than seven times Australia's proposed new ceiling. This divergence matters for Indian consumers because many popular supplement brands sold in India are formulated to US standards, meaning their B6 content reflects the more permissive American benchmark.

Bucchini also pointed to an important nuance: the increase in adverse event reports is not solely explained by higher supplement doses. Improved nutrivigilance systems and greater media and social media attention have both contributed to more consumer reports. "It remains difficult to isolate the cause of the increase in reports," he acknowledged, but said the trend toward more conservative limits is unlikely to reverse.

Why Is Vitamin B6 Added to So Many Products in the First Place?

This is a question the NHMRC's own experts have asked pointedly. Professor Green stated that "vitamin B6 deficiency is rare in Australia because its requirement is quite low and it is widely available in the food supply." The RDI for adults is less than 2mg per day, and most people meet this through a normal varied diet. "There is little justification for routine high-dose supplementation in people without a medical indication," he told Vitafoods Insights.

The same logic applies in India. A balanced diet that includes dal, chicken, fish, bananas, and fortified cereals will comfortably meet the 1.3–1.7mg daily requirement. Clinical B6 deficiency is genuinely rare in populations with access to varied food.

Yet manufacturers have historically added synthetic pyridoxine (the most common supplement form, sold as pyridoxine hydrochloride) at doses far exceeding the RDI because it was cheap, legal, and associated with consumer perceptions of energy, nerve health, and stress relief. Energy drinks, for example, can contain around 5mg of B6 per serving — meaning someone who drinks three or four cans a day while also taking a B-complex and a magnesium supplement could easily exceed even the proposed 14mg ceiling without realising it.

Bucchini was direct in his assessment: "It's not clear that a nutritional need exists, or can be argued in favour of, for super high levels of vitamin B6. Self-regulation would have been better."

What Does "Peripheral Neuropathy from B6 Toxicity" Actually Feel Like?

Peripheral neuropathy is damage to the peripheral nervous system — the network of nerves outside the brain and spinal cord — that disrupts normal sensory and motor signalling. In the context of vitamin B6 toxicity, it is primarily a sensory condition.

The NHMRC draft chapter lists the following symptoms: paraesthesia (pins and needles), hyperaesthesia (heightened sensitivity to touch), numbness, pain, impaired proprioception (sense of body position), sensory ataxia, balance problems, gait disturbance, and in severe cases, difficulty walking. Emerging evidence also suggests that pyridoxine toxicity may involve small fibre neuropathy, which can be associated with autonomic dysfunction, though this evidence is currently limited.

The TGA's own guidance notes a clinically important paradox: the most common symptoms of B6 toxicity closely resemble those of B6 deficiency. Consumers who take high-dose B6 supplements to treat tingling or numbness — believing they are deficient — may actually be worsening the very symptoms they are trying to address. Health professionals are specifically advised to be alert to this scenario.

Evidence suggests a dose-duration relationship: higher intakes cause symptoms sooner, while lower intakes may require longer exposure before harm appears. Symptoms generally improve after stopping supplementation, but in more severe cases, recovery may be incomplete or very slow.

What Should Indian Supplement Buyers Do Right Now?

India does not have a published formal upper limit for vitamin B6, and the Indian Council of Medical Research (ICMR) recommended dietary allowance sits at approximately 2mg per day for adults — consistent with international norms. Indian regulators have not yet signalled any move to restrict high-dose B6 products, but the Australian and European regulatory shift is a practical signal that Indian consumers should not ignore.

Here is what the evidence supports for Indian buyers:

Audit your total daily B6 intake. Check every supplement you take — not just B-complex tablets, but also magnesium supplements, zinc tablets, multivitamins, protein powders, stress-support formulas, and energy drinks. Look for "pyridoxine hydrochloride," "pyridoxal 5-phosphate," or "pyridoxal 5-phosphate monohydrate" on the label. Add up the milligrams across all products.

Compare your total against the proposed 14mg ceiling. If your combined intake from supplements exceeds 14mg per day — even if each individual product appears to contain a "safe" dose — you are above the level that Australia's expert working group considers risk-free for the general population.

Treat high-dose standalone B6 products with particular caution. Products marketed specifically for nerve support, PMS relief, or B6 supplementation often contain 50mg to 100mg per tablet. These are the products most likely to be restricted or reformulated as Australian and European regulations tighten.

Do not self-treat suspected B6 deficiency with high-dose supplements. Because B6 toxicity mimics B6 deficiency, taking more B6 to address tingling or numbness can make the problem worse. A blood test (plasma PLP level) is the most reliable indicator of B6 status and should be ordered by a doctor before supplementation begins.

Watch for reformulated products. As Australian and European manufacturers reformulate to comply with the new limits, products sold in India — which are often the same SKUs or close derivatives — may change their B6 content. Check labels periodically rather than assuming a product you have used for years still contains the same dose.

For broader supplement safety context, our articles on best biotin supplements for skin health and berberine for insulin resistance in India cover similar themes around evidence-based dosing and regulatory context.

What Happens Next in Australia's Regulatory Process?

The NHMRC's 14mg recommendation is currently in public consultation — the standard process by which expert recommendations are tested against industry, consumer, and scientific stakeholder feedback before being finalised. The NHMRC Expert Working Group, whose appointments run until February 2027, will review consultation responses and finalise its recommendations.

Separately, the TGA's June 2027 rescheduling deadline is firm. From that date, pharmacist supervision will be required for products containing 50mg to 200mg per daily dose, and prescriptions will be needed above 200mg. The TGA has stated it will consider further regulatory action once the NHMRC process concludes — meaning a second regulatory tightening is plausible if the 14mg upper limit is formally adopted.

Food Standards Australia New Zealand (FSANZ) will also need to address B6 in fortified foods and beverages. Professor Green flagged energy drinks specifically, noting that a standard serving of some products contains around 5mg of B6, meaning several servings a day could breach the proposed 14mg ceiling. "I can't see why energy drinks should have any B6," he said, though he acknowledged that decision rests with FSANZ rather than the NHMRC.

Professor Green said he did not expect "major resistance from industry" because there is no established commercial or health benefit to providing B6 levels above the proposed upper limit, and responsible manufacturers generally do not want their products contributing to adverse health outcomes.

The Broader Regulatory Trend and What It Means for the Supplement Industry

The Australian review is part of a global recalibration of vitamin B6 safety standards that has been building since EFSA's 2023 downward revision. The direction of travel is clear: regulators in developed markets are moving toward more conservative upper limits, driven by improved adverse event surveillance, better understanding of cumulative exposure, and a growing body of evidence that harm can occur at lower doses than previously assumed.

For the Indian supplement industry — which is growing rapidly and increasingly exports to or imports from regulated markets — this trend carries real consequences. Brands that formulate products to US standards (100mg UL) may find those formulations incompatible with Australian or European market access. Brands that source finished products from Australian or European manufacturers will receive reformulated products with lower B6 content. As Indian regulators develop their own nutrient reference values, the global consensus forming around 12–15mg as a reasonable upper limit will likely influence ICMR's future guidance.

The data from large clinical trials, cited by Professor Green, offers some reassurance: doses of around 10mg to 15mg per day administered over several years have not produced evidence of adverse effects. The proposed 14mg ceiling is not a dramatic restriction for most supplement users — it is primarily a constraint on the high-dose outliers that have driven adverse event reports.

For the average Indian consumer taking a standard B-complex tablet with 2–5mg of B6, the Australian regulatory shift changes nothing practically. The concern is for those stacking multiple supplements, consuming fortified foods and energy drinks, or taking standalone high-dose B6 products for conditions like PMS, nerve pain, or stress — without medical supervision.

Vitamin B6 is an essential nutrient that most people get adequately from food, clinical deficiency is rare, and the evidence for high-dose supplementation in healthy individuals is weak. Australia's proposed 72% cut in the upper limit is a proportionate response to a documented public health problem — and a signal that the era of uncritical high-dose B6 supplementation is ending in regulated markets worldwide.